# Clinical Study of MNC-168 Enteric-coated Capsule in the Treatment of Advanced Intestinal Solid Tumor

> **NCT05383703** · PHASE1 · COMPLETED · sponsor: **Moon (Guangzhou) Biotechnology Co., Ltd.** · enrollment: 12 (actual)

## Conditions studied

- Advanced Malignant Solid Tumors

## Interventions

- **DRUG:** Treatment of MNC-168 enteric-coated capsules as a single oral drug

## Key facts

- **NCT ID:** NCT05383703
- **Lead sponsor:** Moon (Guangzhou) Biotechnology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-28
- **Primary completion:** 2024-07-01
- **Final completion:** 2024-07-04
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2025-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05383703

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05383703, "Clinical Study of MNC-168 Enteric-coated Capsule in the Treatment of Advanced Intestinal Solid Tumor". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05383703. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*